Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study

SIMPLE SUMMARY: This prospective, multicenter study aimed to investigate the efficacy and safety of a front-line treatment with the ibrutinib and rituximab combination in 146 unfit patients with chronic lymphocytic leukemia (CLL). We observed an OR, CR, and 48-month PFS rates of 87%, 22.6%, and 77%,...

Descripción completa

Detalles Bibliográficos
Autores principales: Mauro, Francesca Romana, Paoloni, Francesca, Molica, Stefano, Reda, Gianluigi, Trentin, Livio, Sportoletti, Paolo, Marchetti, Monia, Pietrasanta, Daniela, Marasca, Roberto, Gaidano, Gianluca, Coscia, Marta, Stelitano, Caterina, Mannina, Donato, Di Renzo, Nicola, Ilariucci, Fiorella, Liberati, Anna Marina, Orsucci, Lorella, Re, Francesca, Tani, Monica, Musuraca, Gerardo, Gottardi, Daniela, Zinzani, Pier Luigi, Gozzetti, Alessandro, Molinari, Annalia, Gentile, Massimo, Chiarenza, Annalisa, Laurenti, Luca, Varettoni, Marzia, Ibatici, Adalberto, Murru, Roberta, Ruocco, Valeria, Del Giudice, Ilaria, De Propris, Maria Stefania, Della Starza, Irene, Raponi, Sara, Nanni, Mauro, Fazi, Paola, Neri, Antonino, Guarini, Anna, Rigolin, Gian Matteo, Piciocchi, Alfonso, Cuneo, Antonio, Foà, Robin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8750939/
https://www.ncbi.nlm.nih.gov/pubmed/35008372
http://dx.doi.org/10.3390/cancers14010207

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8750939/
https://www.ncbi.nlm.nih.gov/pubmed/35008372
http://dx.doi.org/10.3390/cancers14010207

Ejemplares similares